First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): Updated results for KEYNOTE-427 cohort A.

被引：14
|
作者：
Tykodi, Scott S.
Donskov, Frede
Lee, Jae-Lyun
Szczylik, Cezary
Malik, Jahangeer
Alekseev, Boris Yakovlevich
Larkin, James M. G.
Matveev, Vsevolod Borisovich
Gafanov, Rustem
Tomczak, Piotr
Geertsen, Poul F.
Wiechno, Pawel J.
Shin, Sang Joon
Pouliot, Frederic
Alonso-Gordoa, Teresa
Silverman, Rachel Kloss
Perini, Rodolfo F.
Schloss, Charles
McDermott, David F.
Atkins, Michael B.
机构：
[1] Univ Washington, Seattle, WA 98195 USA
[2] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA
[3] Aarhus Univ Hosp, Aarhus, Denmark
[4] Asan Med Ctr, Seoul, South Korea
[5] Univ Ulsan, Coll Med, Seoul, South Korea
[6] Postgrad Educ Ctr Oncol, Ecz Otwock, Poland
[7] Western Gen Hosp, Edinburgh Canc Ctr, Edinburgh, Midlothian, Scotland
[8] Minist Hlth Russian Federat, PA Herzen Moscow Oncol Res Inst, Moscow, Russia
[9] Inst Canc Res, London, England
[10] NN Blokhin Russian Canc Res Ctr, Moscow, Russia
[11] Russian Sci Ctr Roentgenoradiol, Moscow, Russia
[12] Poznan Univ Med Sci, Clin Hosp 1, Poznan, Poland
[13] Univ Copenhagen, Herlev Hosp, Herlev, Denmark
[14] Maria Sklodowska Curie Mem Canc Ctr, Warsaw, Poland
[15] Yonsei Univ, Coll Med, Seoul, South Korea
[16] Univ Laval, Quebec City, PQ, Canada
[17] Hosp Univ Ramon y Cajal, Madrid, Spain
[18] Merck & Co Inc, Kenilworth, NJ USA
[19] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[20] Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.4570
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4570
引用
收藏
页数：2
相关论文
共 50 条
  • [1] First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): Updated follow-up for KEYNOTE-427 cohort A.
    McDermott, David F.
    Lee, Jae-Lyun
    Bjarnason, Georg A.
    Larkin, James M. G.
    Gafanov, Rustem
    Kochenderfer, Mark D.
    Jensen, Niels Viggo
    Donskov, Frede
    Malik, Jahangeer
    Poprach, Alexandr
    Tykodi, Scott S.
    Gordoa, Teresa Alonso
    Cho, Daniel C.
    Geertsen, Poul F.
    Duran, Miguel Angel Climent
    Di Simone, Christopher
    Du, Xiaoqi
    Perini, Rodolfo F.
    Rodriguez-Lopez, Karla
    Atkins, Michael B.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [2] First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): Updated follow-up for KEYNOTE-427 cohort A
    Larkin, J. M. G.
    Tykodi, S. S.
    Donskov, F.
    Lee, J-L.
    Szczylik, C.
    Malik, J.
    Alekseev, B. Y.
    Matveev, V. B.
    Gafanov, R. A.
    Tomczak, P.
    Geertsen, P. F.
    Wiechno, P. J.
    Shin, S. J.
    Pouliot, F.
    Alonso Gordoa, T.
    Silverman, R. Kloss
    Perini, R. F.
    Schloss, C.
    McDermott, D. F.
    Atkins, M. B.
    ANNALS OF ONCOLOGY, 2019, 30
  • [3] KEYNOTE-427 cohort A: Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (ccRCC)
    Donskov, F.
    McDermott, D. F.
    Lee, J. L.
    Szczylik, C.
    Malik, J.
    Alekseev, B. Y.
    Larkin, J. M. G.
    Matveev, V. B.
    Gafanov, R. Airatovich
    Tomczak, P.
    Tykodi, S. S.
    Geertsen, P. F.
    Wiechno, P.
    Shin, S. J.
    Pouliot, F.
    Alonso Gordoa, T.
    Silverman, R. Kloss
    Perini, R. F.
    Schloss, C.
    Atkins, M. B.
    ANNALS OF ONCOLOGY, 2018, 29
  • [4] First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (nccRCC): Results from KEYNOTE-427 cohort B.
    McDermott, David F.
    Lee, Jae-Lyun
    Ziobro, Marek
    Gafanov, Rustem Airatovich
    Matveev, Vsevolod Borisovich
    Suarez, Cristina
    Donskov, Frede
    Pouliot, Frederic
    Alekseev, Boris Y.
    Wiechno, Pawel
    Tomczak, Piotr
    Duran, Miguel Angel Climent
    Shin, Sang Joon
    Silverman, Rachel Kloss
    Perini, Rodolfo F.
    Schloss, Charles
    Atkins, Michael B.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [5] First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (nccRCC): Updated follow-up for KEYNOTE-427 cohort B
    Suarez, C.
    Lee, J-L.
    Ziobro, M.
    Gafanov, R. A.
    Matveev, V. B.
    Donskov, F.
    Pouliot, F.
    Alekseev, B. Y.
    Wiechno, P. J.
    Tomczak, P.
    Climent, M. A.
    Shin, S. J.
    Silverman, R. Kloss
    Perini, R. F.
    Schloss, C.
    McDermott, D. F.
    Atkins, M. B.
    ANNALS OF ONCOLOGY, 2019, 30 : 381 - 381
  • [6] Pembrolizumab (pembro) monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (ccRCC): Results after a minimum of 41 months of follow-up from KEYNOTE-427 cohort A
    McDermott, D. F.
    Lee, J-L.
    Bjarnason, G. A.
    Larkin, J.
    Gafanov, R.
    Kochenderfer, M. D.
    Jensen, N. V.
    Donskov, F.
    Malik, J.
    Poprach, A.
    Tykodi, S. S.
    Alonso-Gordoa, T.
    Cho, D. C.
    Geertsen, P. F.
    Climent Duran, M. A.
    Di Simone, C.
    Liu, H.
    Burgents, J.
    Rodriguez-Lopez, K.
    Atkins, M. B.
    ANNALS OF ONCOLOGY, 2021, 32 : S691 - S692
  • [7] KEYNOTE-427 cohort B: First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (NCC-RCC).
    Lee, Jae-Lyun
    Ziobro, Marek
    Gafanov, Rustem
    Matveev, Vsevolod Borisovich
    Suarez, Cristina
    Donskov, Frede
    Pouliot, Frederic
    Alekseev, Boris Yakovlevich
    Wiechno, Pawel J.
    Tomczak, Piotr
    Climent, Miguel Angel
    Shin, Sang Joon
    Silverman, Rachel Kloss
    Perini, Rodolfo F.
    Schloss, Charles
    McDermott, David F.
    Atkins, Michael B.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [8] First-line pembrolizumab (pembro) monotherapy in advanced non-clear cell renal cell carcinoma (nccRCC): Updated follow-up for KEYNOTE-427 cohort B.
    Lee, Jae-Lvun
    Ziobro, Marek
    Suarez, Cristina
    Langiewitz, Przemyslaw
    Matveev, Vsevolod Borisovich
    Wiechno, Pawel
    Gafanov, Rustem
    Tomczak, Piotr
    Pouliot, Frederic
    Donskov, Frede
    Alekseev, Boris
    Shin, Sang Joon
    Bjarnason, Georg A.
    Castellano, Daniel
    Du, Xiaoqi
    Perini, Rodolfo F.
    Rodriguez-Lopez, Karla
    McDermott, David F.
    Atkins, Michael B.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [9] Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (accRCC): Results from cohort A of KEYNOTE-427.
    McDermott, David F.
    Lee, Jae-Lyun
    Szczylik, Cezary
    Donskov, Frede
    Malik, Jahangeer
    Alekseev, Boris Yakovlevich
    Larkin, James M. G.
    Matveev, Vsevolod Borisovich
    Gafanov, Rustem Airatovich
    Tomczak, Piotr
    Tykodi, Scott S.
    Geertsen, Poul F.
    Wiechno, Pawel J.
    Shin, Sang Joon
    Pouliot, Frederic
    Gordoa, Teresa Alonso
    Li, Wenting
    Perini, Rodolfo F.
    Schloss, Charles
    Atkins, Michael B.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [10] Pembrolizumab (pembro) monotherapy as first-line therapy in advanced non-clear cell renal cell carcinoma (nccRCC): Results after a minimum of 34 months of follow-up from KEYNOTE-427 cohort B
    Lee, J-L.
    McDermott, D. F.
    Ziobro, M.
    Suarez, C.
    Langiewicz, P.
    Matveev, V. B.
    Wiechno, P.
    Gafanov, R.
    Tomczak, P.
    Pouliot, F.
    Donskov, F.
    Alekseev, B. Y.
    Shin, S. J.
    Bjarnason, G. A.
    Castellano, D.
    Liu, H.
    Burgents, J.
    Rodriguez-Lopez, K.
    Atkins, M. B.
    ANNALS OF ONCOLOGY, 2021, 32 : S687 - S687
12345